MAP4343 Treatment for Alcohol Use Disorder

Alcohol Use Disorder Clinical Trial

Official title:

A Double-Blind, Randomized, Controlled Trial of MAP4343 Treatment, a Ligand of the Neurospecific Microtubule Associated Protein-2, for Alcohol Use Disorder

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04157114
• Other study ID #: MAP2019
• Secondary ID: P60AA006420
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 2021
• Est. completion date: December 2022

Study information

• Verified date: February 2022
• Source: The Scripps Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, single-site, randomized, double-blind, placebo-controlled, proof-of-concept (POC) study involving 6 weeks of MAP4343 in conjunction with 6 weeks of manual-guided counseling, with 2 follow-up visits at 1 week and 1 month post-treatment.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female volunteers, 18-65 years of age

2. Meets Diagnostic and Statistical Manual (DSM)-5 criteria for current Alcohol Use Disorder (AUD) of moderate or greater severity, defined by DSM-5 as = 4 symptoms

3. In the month prior to screening, reports drinking = 21 standard drinks per week if male, = 14 if female, with at least one heavy drinking day (males: = 5 drinks, females: = 4 drinks) per week

4. Seeking research-based outpatient treatment for AUD and willing to comply with the protocol, take daily oral medication for 6 weeks and complete 10 study visits

5. Abstinent a minimum of 3 days (but not more than 30 days) prior to randomization

6. Negative Blood Alcohol Concentration (BAC) and a Clinical Institute Withdrawal Assessment (CIWA) score of = 9 at randomization

7. In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, electrocardiogram (ECG), urine test, and routine lab tests

8. Females with childbearing potential must have a negative pregnancy test on both the screening and randomization visits and agree to use non-hormonal effective birth control for the study duration and 1 month post treatment.

9. Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent

Exclusion Criteria:

1. Significant medical disorders or clinically significant findings on ECG, urine or blood tests that increase potential risk or interfere with study participation as determined by the Study Physician

2. Liver function tests more than 3 times the upper limit of normal

3. Meets DSM-5 criteria for a major Axis I disorder including mood or anxiety disorders or substance use disorders other than alcohol or nicotine use disorders or mild cannabis use disorder

4. Urine drug test positive at screening for abused drugs other than cannabis. Subjects using cannabis will be excluded if they meet criteria for cannabis use disorder = moderate level of severity

5. Treatment within the month prior to screening with an investigational drug or vaccine, or drugs that may influence study outcomes, e.g., disulfiram, naltrexone, acamprosate

6. Chronic use or need for psychotropic drugs. Note: some drugs with psychotropic properties (e.g., anti-hypertensive drugs) or antidepressant medication taken at a stable dose for = 3 months and no longer meeting criteria for depressive or anxiety disorders are allowed if their use is judged by both the investigator and study physician not to pose a safety risk or impact the results of the study

7. No fixed domicile and/or no availability by home or mobile telephone

8. Treatment mandated by a legal authority

9. Failure to comply with study procedures

10. Subjects who require medical detoxification (Note: Subjects may proceed with study evaluation after completion of detoxification)

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism
• Disease

Intervention

Drug:
• MAP4343
Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
• Placebo
Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling

Behavioral:
• Standardized behavioral counseling
Subjects receive manually-guided counseling 1 time per week for a 6 week duration

Locations

Country	Name	City	State
United States	The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research	La Jolla	California

Sponsors (3)

Lead Sponsor	Collaborator
The Scripps Research Institute	Mapreg, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Timeline Follow-Back (TLFB) Interview	The Timeline Follow-Back Interview provides quantity and frequency estimates of alcohol consumption for the 90-day period prior to and throughout the study.	90-day period prior to and throughout the study
Primary	Visual Analogue Scale of Craving (VAS; adapted from ACQ)	The Visual Analogue Scale of Craving has 4 questions to assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity with a 0-20 point visual analogue scale for each item, with 0 indicating no craving and 20 indicating severe craving.	At subject's Week 2 human laboratory session
Secondary	Alcohol Craving Questionnaire-Short Form (ACQ-SF)	The Alcohol Craving Questionnaire-Short Form has 12 questions about alcohol craving which are each scored 1-7, then summed for a weekly score between 7 and 84, with higher scores indicating greater craving.	Subjects will followed for up to 10 weeks
Secondary	Beck Depression Inventory (BDI-II)	The Beck Depression Inventory II consists of 21 questions assessing depression symptoms answered with scores between 0-3, summed for a weekly total score between 0 and 63, higher scores indicate more depression.	Subjects will be followed for up to 10 weeks
Secondary	Pittsburgh Sleep Quality Index (PSQI)	The Pittsburgh Sleep Quality Index, modified for weekly administration, consists of 9 questions about sleep habits which are answered on a scale of 0-3. Results are sorted into 7 sub scales re-scored 0-3, then sub scales are summed for a weekly total score between 0 and 21, with higher scores indicating greater sleep impairment.	Subjects will be followed for up to 10 weeks
Secondary	State-Trait Anxiety Inventory (STAI)	The State-Trait Inventory has 20 questions for assessing state anxiety and 20 for trait anxiety answered with scores between 1-4, summed for a weekly total score between 20 and 80, higher scores indicate more anxiety.	Subjects will be followed for up to 10 weeks